Tag: #mCRPC

#VisualAbstract: Continued enzalutamide after progression of metastatic prostate cancer improves progression-free survival

byMinjee Kim

October 26, 2022

1. The median progression-free survival was higher in the enzalutamide vs the placebo group (9.5 months vs 8.3 months) 2. ...

#VisualAbstract: Ipatasertib plus abiraterone improves survival in PTEN-negative prostate cancer patients compared to abiraterone alone

byMinjee Kim

July 28, 2021

1. Ipatasertib-abiraterone treatment significantly improved progression-free survival compared to placebo-abiraterone in patients with PTEN-loss metastatic castration-resistant prostate cancer. 2. Grade 3 ...

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

No Result

View All Result

Tag: #mCRPC

#VisualAbstract: Continued enzalutamide after progression of metastatic prostate cancer improves progression-free survival

#VisualAbstract: Ipatasertib plus abiraterone improves survival in PTEN-negative prostate cancer patients compared to abiraterone alone

2MM+ All Access

Recent Reports

The medical literature, distilled daily.

Membership benefits